MedPath

Expressiona and Diagnostic Potential of miRNAs in NSCLC

Completed
Conditions
Non Small Cell Lung Cancer
Registration Number
NCT05815407
Lead Sponsor
Al-Azhar University
Brief Summary

Its to explore the expression pattern, diagnostic and prognostic potentials of miRs (106b-5p, 601 and 760) in serum of NSCLC patients

Detailed Description

A retrospective observational study on NSCLC patients, to determine the serum expression levels if some miRNAs in NSCLC patients and to find if having proper diagnostic and prognostic values in early disease detection, and/or staging.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
100
Inclusion Criteria
  • First time and recently diagnosed NSCLC patient
Exclusion Criteria
  • Recurrent NSCLC
  • Start of chemotherapy, radiotherapy or surgical intervention
  • Previous treatment
  • Cancer history

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Determination of the expressionBy the end of the study (September 2022)

Expression profiling of the selected miRNAs

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt

🇪🇬

Cairo, Egypt

Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt
🇪🇬Cairo, Egypt

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.